IGF1R and plasma cell myeloma: In multiple myeloma (MM), we previously demonstrated that an antagonistic anti-IGF-1R mAb (EM164, also named mAVE1642) can selectively inhibit the growth of CD45neg human myeloma cell lines (HMCLs) (Descamps et al, 2006).